Navigation Links
Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
Date:4/24/2008

BASINGSTOKE, England, April 24 /PRNewswire-FirstCall/ -- The Board of Directors of Shire plc (LSE: SHP) (NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that Michael Rosenblatt M.D. will join the Board as a Non-Executive Director with immediate effect.

Dr Rosenblatt is the Dean of Tufts University School of Medicine, Boston, Massachusetts. He was previously Professor of Medicine at Harvard Medical School and has served in senior research positions at the Beth Israel Deaconess Medical Center in Boston. He was the founding director of the Carl J. Shapiro Institute for Education and Research at Harvard Medical School and Beth Israel Deaconess Medical Center.

In addition, Dr Rosenblatt has served as Director of the Harvard-MIT Division of Health Sciences and Technology and as Senior Vice President for Research at Merck Sharp & Dohme Research Laboratories where he headed a worldwide development team as well as directing drug discovery efforts in the United States, Japan and Italy. In Japan he was responsible for Merck's clinical research and development; he also headed Merck Research's worldwide University and Industry Relations Department.

Earlier in his career, Dr Rosenblatt was Chief of the Endocrine Unit at Massachusetts General Hospital. He is a graduate of Columbia University and gained his medical qualification at Harvard Medical School.

Dr James Cavanaugh, Chairman of Shire commented:

"We are honored to welcome Dr Rosenblatt to the Board of Directors. His impressive medical background and research experience will be of great value as we continue to grow our business through acquisition and product development. As Shire grows its biopharmaceutical portfolio and expands
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
3. Genstar Names Michael Hurt to Its Strategic Advisory Board
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
11. John Marshall and Kevin McGuinness Appointed to Ellex Board

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...Calif., Nov. 6 Calbiotech, Inc. an...iness Innovative Research (SBIR) Phase I contract ...mand. Under terms of the agreement, Calbiotech wil... diagnosis of Dengue virus. ,, Dengue virus ...jor threat to military forces deployed to tropical...
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 Persona...et to take place on February 22-24, 2010 in Philad...erence we will highlight key issues in forming par...eir experiences. , Minnea...or Arrowhead’s 2010 Personalized Medicine P...
(Date:11/5/2009)...o., Nov. 5 The endangered black-fo...ern U.S. This rare carnivore feeds on prairie dog...ue and often entire population die-offs in towns o...has implemented a ferret breeding program and has ... formerly native habitat. Unfortunately, plague c...
(Date:11/5/2009)... Calif., Nov. 5 ThermoGe...f innovative products for processing and storing a...rst quarter of fiscal 2010. ,, For the quarter ...enues of $5.2 million, a 15 percent increase over ...ar ago. The Company said the key contributors to t...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8
...IN LAKES, N.J., March 13 Medco Health,Solutions, ...eed to sell $300,million aggregate principal amoun... and $1.2 billion aggregate principal amount of 7-...underwritten public offering. Citi,J.P. Morgan Sec...arclays,Capital Inc. are acting as representatives...
... Generation Treatment from Abbott Shows No Thrombo...ary Clinical Study of Thirty Patients, ABBOTT PAR...cet from ABSORB, the world,s first clinical trial ...e treatment of coronary artery,disease, demonstrat...t,lesion revascularizations (retreatment of a dise...
...EY, Calif., March 13 Nile Therapeutics,Inc. (OTC ...quarter and,full year financial results for 2007. ...e conference call from the investor relations sect... . The webcast will remain available on,the compan...ll., For the fourth quarter of 2007, Nile reporte...
Other Biology Technology:Medco Issues $1.5 Billion of Senior Notes 2Medco Issues $1.5 Billion of Senior Notes 3The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 2The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 3The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 4Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3
(Date:11/5/2009)...ining grant in the amount of $2,756,719 by the Nat...duation Education and Research Training (IGERT) pr... to Kent State. The grant, which is funded under t... runs through 2014. , The grant funds an IGERT p...e sensing (EARS). The purpose of the program is to...
(Date:11/4/2009)...g Beach and Riverside are responsible for a signif...and the true impact of air pollution and ship emis...d, according to researchers at the University of S...pears in an online edition of the American Journa...f all childhood asthma cases in Long Beach and six...
(Date:11/4/2009)... DNA codes, or genomes, of the famed fugu (or puff...10K Project, an international effort to build an i...ecies of animals for conducting comparative studie..., Participating in The Genome 10K project, descri... of the Journal of Heredity , are 70 leading scie...
Breaking Biology News(10 mins):Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2USC study finds big air pollution impacts on local communities 2Singapore scientists join international study of 10,000 vertebrates' genomes 2Radiology Benefit Management Could Save Medicare up to 2418 Billion Over 10 Years 51941 1Radiology Benefit Management Could Save Medicare up to 2418 Billion Over 10 Years 51941 2Radiology Benefit Management Could Save Medicare up to 2418 Billion Over 10 Years 51941 3Scientists Reverse Muscular Dystrophy in Mice 51938 1Scientists Reverse Muscular Dystrophy in Mice 51938 2Scientists Reverse Muscular Dystrophy in Mice 51938 3Arcadian Chairman and Chief Executive Officer Robert Fahlman to Present at Focus on Healthcare Conference in New York City 51935 1
...y the National Institute on Drug Abuse (NIDA), par...he first time identified genes that might increase...reakthrough research was conducted by Dr. George U...m led by Dr. Jed Rose at the Center for Nicotine a...edical Center. , The study, published in the journ...
... of Allergy and Infectious Diseases (NIAID), part ...announced it is awarding $23 million per year for ... for Influenza Research and Surveillance. Collecti...rveillance program internationally and in the Unit...key areas, including understanding how the virus c...
...n that reduced calorie intake can increase health ...ity of California) and his collaborators* have dis... can still induce many of the health and longevity...tly, this also includes anti-cancer effects. , Th...creening technique to find drugs which mimic this ...
Other Biology News:NIDA study identifies genes that might help some people abstain from smoking 2NIAID expands capability for influenza research and surveillance 2NIAID expands capability for influenza research and surveillance 3NIAID expands capability for influenza research and surveillance 4It's never too late to get it back! Aging interrupted 2
Luminex 100 IS System from Luminex Corporation
GIBCO Water distilled from Invitrogen
Rabbit Anti-Bovine Respiratory Syncytial Virus Bovine Respiratory Syncytial Virus Antibody, Unconjugated from ABR-Affinity BioReagents
Rabbit Anti-MacMarcks Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Biology Products: